Latest Hotspot

Initial Participant Receives First Treatment in Henlius' HLX42 ADC Early-Stage Study

21 March 2024
3 min read

Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant. HLX42 is a novel antibody-drug conjugate directed at EGFR, currently under investigation for its efficacy in managing advanced or metastatic solid tumors.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The pharmaceutical entity HLX42, a product of the joint venture between MediLink Therapeutics and the initiating company, has received authorization from both the National Medical Products Administration and the U.S. Food and Drug Administration to embark on clinical trials.

By the close of December 2023, the U.S. FDA had acknowledged the significance of HLX42 by bestowing upon it the Fast Track Designation for its role in managing patients struggling with advanced or metastatic non-small cell lung cancer who have not seen improvement with EGFR targeted treatments.

Despite impressive strides made with monoclonal antibodies against EGFR and third-generation EGFR Tyrosine kinase inhibitors, research indicates that new treatments are imperative for patients who demonstrate resistance or relapse following conventional therapy regimens.

HLX42 is engineered as an innovative ADC targeting EGFR. Its architecture includes a humanised IgG1 monoclonal antibody with high affinity for EGFR, linked to a groundbreaking toxic agent via cleavable connections, and it boasts a drug-to-antibody ratio of approximately 8.

Through its robust anti-tumour efficacy demonstrated in various CDX and PDX models resistant to established EGFR TKIs or cetuximab, HLX42 promises to address the challenge of resistance to current EGFR targeting treatments, thereby serving the significant therapeutic requirements of a broader patient group afflicted with advanced or metastatic solid tumours.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, Word

描述已自动生成

According to the data provided by the Synapse Database, As of March 19, 2024, there are 641 investigational drugs for the EGFR target, including 467 indications, 687 R&D institutions involved, with related clinical trials reaching 6048, and as many as 67688 patents.

HLX-42 targets the EGFR and aims to treat solid tumors, specifically EGFR-mutated non-small cell lung cancer. The drug is currently in Phase 1 of clinical development both globally and in China. Further research and development will be needed to assess the safety and efficacy of HLX-42 in larger patient populations and to progress to later stages of clinical testing.

图形用户界面, 文本, 应用程序

描述已自动生成

Strategically Search Chlorthalidone on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Chlorthalidone on Synapse: A How-to Guide
21 March 2024
Chlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys.
Read →
Formycon and Fresenius Kabi Reach Agreement on Ustekinumab Biosimilar FYB202 for European and Canadian Markets
Latest Hotspot
2 min read
Formycon and Fresenius Kabi Reach Agreement on Ustekinumab Biosimilar FYB202 for European and Canadian Markets
21 March 2024
Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
21 March 2024
The article will discuss GPCR targets and noteworthy pipelines from Roche and TEVA at JPM Healthcare 2024.
Read →
Tunlametinib (HL-085): First Targeted Therapy for Advanced Melanoma with NRAS Mutation Approved Post PD-1/PD-L1 Treatment
Latest Hotspot
3 min read
Tunlametinib (HL-085): First Targeted Therapy for Advanced Melanoma with NRAS Mutation Approved Post PD-1/PD-L1 Treatment
21 March 2024
KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.